Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia

Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemia

Abstract Background A tyrosine kinase inhibitor (TKI) such as Imatinib (IM) is the preferred treatment for Chronic Myeloid Leukemia (CML). However, the emergence of IM resistance presents a significant challenge to disease management. A characteristic of cancer cells, including IM-resistant CMLs, ar...

Full description

Saved in:
Bibliographic Details
Main Authors: Hongpeng Duan, Qian Lai, Yuelong Jiang, Liuzhen Yang, Manman Deng, Zhijuan Lin, Weihang Shan, Mengya Zhong, Jingwei Yao, Li Zhang, Bing Xu, Jie Zha
Format: Article
Language:English
Published: BMC 2024-12-01
Series:Experimental Hematology & Oncology
Subjects:
Chronic myeloid leukemia
Glucose metabolism
Imatinib resistance
Chiglitazar
PPARγ
Online Access:https://doi.org/10.1186/s40164-024-00589-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items